News
Bitget bietet ein unvergessliches Erlebnis: VIP-Zugang zum Karate Combat KC54 UFC-Kampf in Dubai
DUBAI, Vereinigte Arabische Emirate, May 27, 2025 (GLOBE NEWSWIRE) -- Bitget, die führende Kryptowährungsbörse und Web3-Firma, hat mit einem exklusiven Erlebnis am Ringrand beim Karate Combat
Evotec Stock: Dramatic Rebound Sparks Takeover Speculation
After a prolonged downward spiral, Evotec shares have mounted an impressive comeback, surging 15-17% to reach €8.24—their highest level since early March. This remarkable rally follows a brief dip
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking
3 Trades Members of Congress Are Making Right Now
Whether or not members of Congress should be allowed to buy or sell stocks is another topic. Retail investors should keep their eyes on the ball. That means, if investors can’t beat them, they may
3 Trades Members of Congress Are Making Right Now
Whether or not members of Congress should be allowed to buy or sell stocks is another topic. Retail investors should keep their eyes on the ball. That means, if investors can’t beat them, they may
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more
EQS-News: Eckert & Ziegler zum zweiten Mal mit „Best Managed Companies Award“ ausgezeichnet
EQS-News: Eckert & Ziegler zum zweiten Mal mit „Best Managed Companies Award“ ausgezeichnet
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the one-sided machine it used to be a few decades ago. Thanks to the flow of
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the one-sided machine it used to be a few decades ago. Thanks to the flow of
Sanofi Stock: $600M Alzheimer Drug Acquisition Bet
Sanofi has made a strategic move to strengthen its neurology portfolio by acquiring Vigil Neuroscience for up to $600 million. The French pharmaceutical giant will pay $470 million ($8 per share)
Sanofi Stock: $600M Alzheimer Drug Acquisition Bet
Sanofi has made a strategic move to strengthen its neurology portfolio by acquiring Vigil Neuroscience for up to $600 million. The French pharmaceutical giant will pay $470 million ($8 per share)
Sanofi Stock: $600M Alzheimer Drug Acquisition Bet
Sanofi has made a strategic move to strengthen its neurology portfolio by acquiring Vigil Neuroscience for up to $600 million. The French pharmaceutical giant will pay $470 million ($8 per share)
EuroPCR 2025: Aktuelle Daten belegen: Die Ereignisraten nach drei Jahren sind beim DynamX® Bioadaptor von Elixir Medical anhaltend signifikant niedriger als bei medikamentenfreisetzenden Stents
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- – Anhaltende Dauerhaftigkeit des Behandlungseffekts bei signifikant niedrigeren TLF-Raten (2,7 % vs. 7,2 %, p = 0,030) bei DynamX® im Vergleich zu DES –
–
Viking Holdings Posts Strong Q1, Eyes Growth Ahead
Viking Holdings Inc. (NASDAQ: VIK) is a relative newcomer to investors. The cruise line, known for its longships and child-free cruises, completed its initial public offering (IPO) in April 2024.
Pfizer Stock: Billion-Dollar Chinese Cancer Drug Deal
Pharmaceutical giant Pfizer is making significant strategic moves in oncology, investing up to $6 billion in a licensing deal with Chinese biotech firm 3SBio. The agreement centers on SSGJ-707, a
Pfizer Stock: Billion-Dollar Chinese Cancer Drug Deal
Pharmaceutical giant Pfizer is making significant strategic moves in oncology, investing up to $6 billion in a licensing deal with Chinese biotech firm 3SBio. The agreement centers on SSGJ-707, a
Santheras Aktionäre stimmen an der heutigen Generalversammlung allen Anträgen des Verwaltungsrats zu
Pratteln, Schweiz, 20. Mai 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt heute bekannt, dass die Aktionäre an der heutigen Generalversammlung (GV) in Pratteln, Schweiz, allen Anträgen des
EQS-HV: STRATEC SE: Bekanntmachung der Einberufung zur Hauptversammlung am 27.06.2025 in Virtuelle Hauptversammlung mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Regeneron Stock: Pharma Giant Bets on Genetic Data
Regeneron Pharmaceuticals is set to acquire the bankrupt genetic testing company 23andMe for $256 million, gaining access to a massive database of 15 million DNA profiles. The bold move, announced
Regeneron Stock: Pharma Giant Bets on Genetic Data
Regeneron Pharmaceuticals is set to acquire the bankrupt genetic testing company 23andMe for $256 million, gaining access to a massive database of 15 million DNA profiles. The bold move, announced
Regeneron Stock: Pharma Giant Bets on Genetic Data
Regeneron Pharmaceuticals is set to acquire the bankrupt genetic testing company 23andMe for $256 million, gaining access to a massive database of 15 million DNA profiles. The bold move, announced
Basilea gibt Verkaufsstart seines Antibiotikums Zevtera® (Ceftobiprol) in den USA bekannt
Allschwil, 20. Mai 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren
UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
Despite the healthcare sector's reputation for stability, UnitedHealth Group (NYSE: UNH) has recently faced significant market turbulence.
By mid-May